Reconstructing the course of the COVID-19 epidemic over 2020 for US states and counties: results of a Bayesian evidence synthesis model

2 3

> 8 9

17

1

4
Authors: Melanie H. Chitwood¹[¶]*, Marcus Russi¹[¶], Kenneth Gunasekera¹, Joshua Havumaki¹,
Fayette Klaassen², Virginia E. Pitzer¹, Joshua A. Salomon³, Nicole A. Swartwood³, Joshua L.
Warren⁴, Daniel M. Weinberger¹, Ted Cohen^{1&} and Nicolas A. Menzies^{2&}

Affiliations:

- ¹Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale
- 11 School of Public Health, Yale University, New Haven, Connecticut USA
- ¹² ²Department of Global Health and Population, Harvard T.H. Chan School of Public Health,
- 13 Harvard University, Boston, Massachusetts US
- ³Department of Medicine, Stanford University, Stanford, California USA
- ⁴Department of Biostatistics and Public Health Modeling Unit, Yale School of Public Health,
- 16 Yale University, New Haven, Connecticut USA
- 18 [¶]These authors contributed equally to this work
- 19 [&]These authors share senior authorship
- 20 ^{*}Corresponding author
- 21 Email: <u>melanie.chitwood@yale.edu</u>

22 Abstract

23	Reported COVID-19 cases and deaths provide a delayed and incomplete picture of SARS-CoV-2
24	infections in the United States (US). Accurate estimates of both the timing and magnitude of
25	infections are needed to characterize viral transmission dynamics and better understand COVID-
26	19 disease burden. We estimated time trends in SARS-CoV-2 transmission and other COVID-19
27	outcomes for every county in the US, from the first reported COVID-19 case in January 13, 2020
28	through January 1, 2021. To do so we employed a Bayesian modeling approach that
29	explicitly accounts for reporting delays and variation in case ascertainment, and generates daily
30	estimates of incident SARS-CoV-2 infections on the basis of reported COVID-19 cases and
31	deaths. The model is freely available as the covidestim R package. Nationally, we estimated there
32	had been 49 million symptomatic COVID-19 cases and 400,718 COVID-19 deaths by the end of
33	2020, and that 27% of the US population had been infected. The results also demonstrate wide
34	county-level variability in the timing and magnitude of incidence, with local epidemiological
35	trends differing substantially from state or regional averages, leading to large differences in the
36	estimated proportion of the population infected by the end of 2020. Our estimates of true
37	COVID-19 related deaths are consistent with independent estimates of excess mortality, and our
38	estimated trends in cumulative incidence of SARS-CoV-2 infection are consistent with trends in
39	seroprevalence estimates from available antibody testing studies. Reconstructing the underlying
40	incidence of SARS-CoV-2 infections across US counties allows for a more granular
41	understanding of disease trends and the potential impact of epidemiological drivers.
42	

43 Introduction

44	The numbers of newly diagnosed cases and confirmed COVID-19 deaths are the most easily
45	observed measures of the health burden associated with COVID-19 and have been widely used
46	to track the trajectory of the epidemic at the national, state, and local level. ^{1,2} However, there are
47	at least three limitations of using reported cases and deaths for this purpose. First, testing is
48	primarily organized to identify symptomatic individuals, but a large fraction of SARS-CoV-2
49	infections are asymptomatic, ³ leading to case counts that are substantially smaller than the true
50	incidence of infection. Second, the degree to which case counts undercount infections is sensitive
51	to the availability and utilization of diagnostic testing, which has varied over time and
52	geography. ^{4,5,6} For this reason, it can be difficult to distinguish true trends from changes in
53	testing practices. Third, case and death counts are lagging indicators of the transmission
54	dynamics of the pathogen, as they are affected by delays associated with the incubation period,
55	care-seeking behavior of symptomatic individuals, diagnostic processing times, and reporting
56	practices. Taken together, these limitations present challenges to analyses that rely on these
57	metrics as primary signals of SARS-CoV-2 spread.
58	A better indicator of changes in local transmission is the effective reproduction number (R_t) ,
59	which represents the average number of secondary infections caused by an individual infected at
60	some time t . ⁷ R_t can signal short-term changes in transmission in response to policy and
61	behavioral changes. However, R_t is not a directly observable quantity and estimates of R_t based
62	on raw case reports become biased when reporting delays are incorrectly estimated, ⁵ weakening
63	their usefulness as a measure of transmission.

65	insight into the size and scope of the United States (US) epidemic and inform current and future
66	COVID-19 control policies. A number of modeling approaches have been developed to
67	reconstruct the time series of infections and deaths over the course of the US epidemic. These
68	approaches typically do not allow for variability in case ascertainment and infection fatality
69	ratios (IFRs) across space and time, nor do they attempt to model SARS-CoV-2 infections or
70	COVID-19 deaths at fine spatial scales, such as at the county level. ^{8,9}
71	Here, we present detailed estimates of viral dynamics for all US states and counties, based on a
72	Bayesian statistical model that combines multiple data sources to estimate SARS-CoV-2
73	infection patterns from observed case notifications and death reports. We apply our model to
74	publicly available COVID-19 case and death data and report on the trajectory of the epidemic
75	from the first reported case (January 13, 2020) until January 1, 2021. The model is available on
76	GitHub (https://github.com/covidestim/covidestim/) as a package for the R programming
77	language (covidestim).

78 **Results**

79 Analytic Overview

80 We developed a mechanistic model to back-calculate SARS-CoV-2 infections and subsequent

81 outcomes based on reported COVID-19 cases and deaths. In this model the natural history of

- 82 COVID-19 is represented using four health states: asymptomatic or pre-symptomatic SARS-
- 83 CoV-2 infection (*Asymptomatic*), symptomatic but not severe COVID-19 disease (*Symptomatic*),
- 84 severe COVID-19 disease (*Severe*), and death from COVID-19 (*Death*). In each health state
- 85 (except *Death*) individuals either recover or transition to a more severe state after some delay.

86	Infected individuals can be diagnosed in the Asymptomatic, Symptomatic, or Severe states, and
87	we assume all diagnosed cases and all deaths among diagnosed individuals are reported after as
88	short delay. Figure 1 shows modeled health states and transitions. The model generates several
89	outcomes of epidemiological importance, including R_t , total infections, symptomatic cases, total
90	deaths, and case ascertainment; we estimated these outcomes for each US state and county from
91	the start of the epidemic until January 1, 2021.
92	Figure 1: A model schematic of the main health states: Asymptomatic (denoted
93	"Asymp."), Symptomatic (denoted "Symp."), Severe, and Death. The subscript "dx"
94	indicates that individuals in that state have received a diagnosis of COVID-19. Each
95	transition (denoted with an arrow) has an associated probability and delay distribution.
96	Solid arrows denote disease progression; dotted arrows denote recovery; short dashed
97	arrows denote diagnosis; long dashed arrows denote reporting. All diagnosed cases and
98	deaths are assumed to be reported after a given delay.
99	

100 Main Findings

101 Incidence and R_t

The SARS-CoV-2 epidemic in the US consisted of a series of related outbreaks, which varied greatly in both the intensity of transmission and the extent of geographic spread (Figure 2). The March outbreak in New York State was the largest per population in a single state; on March 28, we estimate that New York State had 812 (95% credible interval: 477, 1393) infections per 106 100,000, and 39% (23%, 68%) of all infections in the US on that day. Local surges in infections during the fall and winter of 2020 rivaled New York's March outbreak in scale, but occurred in

108	the context of a more generalized US epidemic. South Dakota, for example, had its highest per
109	capita infections of 2020 on November 7 (628 [405, 1009] infections per 100,000), but
110	accounted for just 1.2% (0.8%, 2.0%) of all US infections that day. Forty-five states experienced
111	the highest daily infections per capita in November or December (Figure 3).
112	Figure 2: Panels 1-10: County-level infections per 100,000 population per day at 10
113	timepoints between April 1, 2020 and January 1, 2021. Panel 11: Time series of national
114	SARS-CoV-2 infection estimates (orange line) and reported COVID-19 diagnoses (blue
115	bars) per 100,000 people per day from March 1, 2020 to January 1, 2021.
116	Figure 3: Incident infections per 100,000 residents per day for each US state from March
117	1, 2020 to January 1, 2021. Shaded areas represent 95% credible intervals.
118	While most states and counties had lower levels of transmission during the summer months, few
119	achieved established thresholds of low levels of community transmission, defined as fewer than
120	20 confirmed cases per 100,000 per week. ¹⁰ We estimate that only six states (Alaska, Hawaii,
121	Montana, Oregon, Vermont, and West Virginia) had fewer than 20 symptomatic cases per
122	100,000 inhabitants per week after transmission was established locally. Notably, Vermont
123	remained below this threshold from the week of April 27 until the week of October 5.
124	Estimates of R_t at the start of the epidemic varied greatly by state. The median state-level
125	estimate of R_t on the first day a case was reported in each state was 4.9 (range: 2.0 [1.7 – 2.4] in
126	Washington to 11.4 [7.4–18.9] in New York). Throughout April, R_t estimates dropped
127	substantially. Over the period May 1, 2020 to January 1, 2021, state-level estimates of R_t ranged
128	from 0.6 (0.5, 0.8) to 1.7 (1.4, 2.0) (Figure 4).

129	Figure 4: R_t estimates for each US state from March 1, 2020 to January 1, 2021.
130	Background colors indicate whether R_t is substantially greater than 1 (red), close to 1
131	(white), or substantially less than 1 (blue). Grey line indicates $R_t = 1$. Shaded areas
132	represent 95% credible intervals.

133 Percent Ever-Infected with SARS-CoV-2

134 For each county, we calculated the percentage of the population ever-infected as the sum of all

estimated infections divided by county population on January 1, 2021 (Figure 5). This

136 cumulative infection estimate is distinct from reported seroprevalence estimates, as

137 seroprevalence measures may be affected by the lower immune response among individuals with

138 mild/asymptomatic infection, possible waning of antibody titers,^{11,12} and non-representativeness

139 of sampled populations.¹³ By January 1 2021, we found that the percent of the population ever-

140 infected exceeded 50% in 241 (7.7%) counties and exceeded two-thirds of the population in 22

141 (0.7%) counties. Conversely, the percent ever-infected was less than 10% in 145 (4.6%) counties

and less than 5% in 34 (1.1%) counties. Based on the sum of state estimates (posterior medians),

143 we estimate that 27% of the US population had been infected with SARS-CoV-2 by January 1,

144 2021. Across states, the percent ever-infected ranged from 6.7% (4.4%, 10.9%) in Vermont to in

145 44.6% (30.0%, 66.5%) Arizona (Figure 3).

146 On January 1, 2021, the US had reported 349,247 cumulative COVID-19 deaths.¹⁴ Based on the

sum of state estimates (posterior medians), we estimate there were 400,718 cumulative COVID-

- 148 19 deaths as of January 1, 2021, 14.7% greater than cumulative reported deaths and
- 149 approximately 0.12% of the US population on January 1, 2020. Estimates of the size of the

- 150 infected population were sensitive to assumptions about the infection fatality rate, with higher151 IFR values producing lower estimates of the infected population (Figure S1).
- Figure 5: Percentage of the population ever-infected with SARS-CoV-2 as of January 1,
 2021.
- 154 *Case Ascertainment*

155	The probability that an infection is diagnosed changed substantially over the course of the U.S.
156	epidemic. Ascertainment was low in the months of March, April, and May 2020. The national
157	median state-level case ascertainment (based on state-level posterior medians) in this period was
158	14% (range: 3.8%, 41.2%). Infection ascertainment improved steadily through June 2020 before
159	plateauing; the national mean probability of diagnosis fluctuated between 24% and 37% between
160	July 1, 2020 and January 1, 2021. Infection ascertainment estimates varied significantly across
161	states, and state-level estimates were highly uncertain (Figure 6). Only 5 states achieved greater
162	than 50% ascertainment at any point in time (based on posterior median). State-level model
163	estimates of infection ascertainment each day are very weakly correlated with the seven-day
164	moving average fraction of tests that have a positive result (Spearman rank correlation (ρ) = -
165	0.10, $p < 0.001$). From the introduction of SARS-CoV-2 in the US until January 1, 2021, we
166	estimate that 22.9% of infections were identified and reported.

Figure 6: The probability that a person infected with SARS-CoV-2 on a given day will
be diagnosed for each US state from March 1, 2020 to January 1, 2021. Shaded areas
represent 95% credible intervals.

170 Comparisons to External Covid-19 Burden Indicators

171	We compared our estimates of the percent ever-infected with SARS-CoV-2 to U.S. Centers for
172	Disease Control (CDC) seroprevalence estimates drawn from commercial laboratory data, ¹⁵
173	acknowledging previously noted differences between these different outcomes. Derived from a
174	convenience sample of blood specimens collected for reasons unrelated to COVID-19, the
175	seroprevalence estimates provide state-level evidence on SARS-CoV-2 antibody test positivity at
176	multiple time points (Figure 7). However, these estimates are incomplete in some states (e.g.
177	South Dakota), and the series of values declines over time in others (e.g. New York). Comparing
178	these estimates to other reported indicators of cumulative disease burden on January 1 2021, the
179	modeled estimates of the percent ever-infected were more strongly correlated with cumulative
180	hospitalizations (Spearman rank correlation (ρ) = 0.60) and cumulative reported deaths (ρ =
181	0.81) than the CDC seroprevalence estimates ($\rho = 0.41$ and 0.37 for hospitalizations and deaths
182	respectively).
183	Figure 7: Comparison of the estimated percent ever-infected with SARS-CoV-2 (purple
184	line, shaded areas represent 95% credible intervals) to CDC seroprevalence estimates
185	from commercial laboratory data (red vertical line) and cumulative reported cases (black
186	line) for each US state from March 1, 2020 to January 1, 2021.
187	In addition, we compared model estimates of cumulative COVID-19 deaths (detected and
188	undetected) to state-level estimates of excess all-cause mortality, which reflect both COVID-19
189	deaths and deviations from expected levels and patterns in non-COVID-19 deaths, ⁶ (Figure 8) at

- 190 each weekly timepoint from March 7 to December 19, 2020. On average, modeled estimates of
- 191 cumulative COVID-19 deaths are less than or approximately equal to estimates of excess all-
- 192 cause mortality. Notably, three states (Alaska, Hawaii, Maine) have extended periods where the
- 193 estimated all-cause mortality did not exceed all-cause mortality from previous years (i.e. excess

194	mortality was negative); in periods where all-cause mortality is higher than expected, our
195	estimates of COVID-19 deaths correlate strongly with excess mortality estimates (Spearman
196	rank correlation (ρ) = 0.96, p < 0.001). Additionally, model estimates of cumulative COVID-19
197	deaths exceed estimates of excess all-cause mortality in two states (Massachusetts and Rhode
198	Island). Estimates of excess all-cause mortality were not available for Connecticut, North
199	Carolina, or West Virginia.

200	Figure 8: Comparison of cumulative COVID-19 deaths (blue) to cumulative excess all-
201	cause mortality (red) for each US state from March 7 to December 19, 2020. Shaded
202	areas represent 95% credible intervals.

203 **Discussion**

204 We present detailed estimates of the dynamics of SARS-CoV-2 infections in US states and 205 counties through the end of 2020. We found that the viral dynamics are best described as a series 206 of related local and regional epidemics, differing in their timing and magnitude even within 207 individual states. This is evident in the large variation in state- and county-level estimates of 208 percent ever-infected as of January 1, 2021. As case ascertainment has also varied over space 209 and time, these estimates provide insights beyond those that can be inferred from cumulative 210 case counts alone. Ascertainment of infection improved markedly after the first months of the 211 US epidemic, but remained low nationally; we conclude that the reported cumulative case count 212 was approximately one-quarter of the true number of US infections at the end of 2020.

Most notably, we found that model estimates of cumulative infections differ from seroprevalence estimates produce by the CDC. We note that our estimates of cumulative infections are more strongly correlated with cumulative hospitalizations and deaths across states, potentially

216	reflecting biases in the empirical seroprevalence estimates. Seroprevalence studies have a
217	number of known limitations, including the use of non-representative samples ¹³ and possible
218	reduced sensitivity associated with waning of antibody titers, as has been reported for some
219	tests. ^{11,12} A comparison between model estimates and seroprevalence data therefore suggests that
220	this method provides valuable information about the incidence of infection over time.

221 The Bayesian estimation approach used for this analysis makes a number of simplifying 222 assumptions. To reduce model complexity, we rely on fixed distributions to describe delays in 223 disease progression and detection. Because we anchor the analysis on death data (under the 224 assumption that deaths were more consistently reported than cases over the course of the 225 epidemic), model estimates are sensitive to infection fatality risk (IFR) estimates, which are 226 themselves uncertain. Finally, we assume that a previously infected individual cannot be re-227 infected with SARS-CoV-2. While waning antibody titers suggest that re-infection is possible 228 over time, we do not believe that our assumptions about re-infection meaningfully impact our results.^{16,17} 229

230 In addition, we used data that have been aggregated from state-level reporting mechanisms, 231 which are vulnerable to a number of potential sources of bias. States vary in their reporting 232 criteria (e.g. reporting the number of positive tests as opposed to number of individuals who have 233 tested positive) and the average delay between case detection and reporting. Data are also subject 234 to occasional revisions, often implemented as a single-day change in the cumulative count of 235 cases or deaths. Taken together, these data irregularities lead to additional variance in the 236 reported data and a reduction in the precision of reported estimates. While line-list data would likely improve the precision of model estimate¹⁸, these data are not widely available in the US, 237 238 and it is not possible to generate the results presented here from a method which relies solely on

239	line-list data. Despite these limitations, the method described here may represent an
240	improvement over similar modeling approaches that do not allow for case ascertainment rates
241	and infection fatality ratios that vary over both space and time, 8,9,19,20 or that estimate R_t using
242	model outputs rather than as part of the modeling framework. ^{9,18,20} Furthermore, our approach
243	uses changes in case and death data to estimate changes in transmission, while others approaches
244	make use of more indirect data on mobility ^{8,19} or similar proxies ²⁰ to signal changes in
245	transmission. While mobility has a mechanistic relationship with disease transmission, the
246	association between movement data and viral transmission is complex, possibly because of
247	changes in mask use and other non-pharmaceutical interventions, and was an increasingly poor
248	predictor of transmission as the epidemic progressed in the US. ^{21,22}
240	In some busies, the modeling engaged described have marriades a schement frequency of for
249	In conclusion, the modeling approach described here provides a coherent framework for
249 250	In conclusion, the modeling approach described here provides a coherent framework for simultaneously estimating the trend in SARS-CoV-2 infections and the fraction of the population
250	simultaneously estimating the trend in SARS-CoV-2 infections and the fraction of the population
250 251	simultaneously estimating the trend in SARS-CoV-2 infections and the fraction of the population that has been infected previously, providing key information on the viral dynamics at county-
250 251 252	simultaneously estimating the trend in SARS-CoV-2 infections and the fraction of the population that has been infected previously, providing key information on the viral dynamics at county- and state-levels. While the deployment of effective vaccines against the virus represents a great
250 251 252 253	simultaneously estimating the trend in SARS-CoV-2 infections and the fraction of the population that has been infected previously, providing key information on the viral dynamics at county- and state-levels. While the deployment of effective vaccines against the virus represents a great hope for the control of SARS-CoV-2 transmission, vaccine hesitancy and the emergence of more
250 251 252 253 254	simultaneously estimating the trend in SARS-CoV-2 infections and the fraction of the population that has been infected previously, providing key information on the viral dynamics at county- and state-levels. While the deployment of effective vaccines against the virus represents a great hope for the control of SARS-CoV-2 transmission, vaccine hesitancy and the emergence of more transmissible variants ²³ present an ongoing challenge to disease control in the US. Understanding
 250 251 252 253 254 255 	simultaneously estimating the trend in SARS-CoV-2 infections and the fraction of the population that has been infected previously, providing key information on the viral dynamics at county- and state-levels. While the deployment of effective vaccines against the virus represents a great hope for the control of SARS-CoV-2 transmission, vaccine hesitancy and the emergence of more transmissible variants ²³ present an ongoing challenge to disease control in the US. Understanding the course of the epidemic in the pre-vaccine era can help guide decision making in a landscape

258 Methods

We developed a mechanistic model that uses reported case and death data to back-calculate the natural history cascade of SARS-CoV-2. The model estimates the expected number of cases and

261	deaths reported on a given day as the convolution of the time series of diagnosed cases and
262	deaths (among diagnosed individuals) and fixed reporting delay distributions; the expected
263	number of diagnoses on a given day is estimated with health-state specific and time-varying
264	probabilities of diagnosis. The model represents the natural history of COVID-19 as a series of
265	health state transitions with associated probabilities and delays (Figure 1). The model utilizes
266	delay distributions associated with health state progression, time-invariant probabilities of
267	transitioning from Asymptomatic to Symptomatic and from Symptomatic to Severe, and a time-
268	varying probability of transitioning from Severe to Death. The number of individuals entering
269	Asymptomatic is a function of the serial interval, the fraction of the population not yet infected,
270	and R_t ; R_t is modeled using a log-transformed cubic b-spline.
271	Data
271 272	Data For every state and county in the United States, we extracted daily data on reported COVID-19
272	For every state and county in the United States, we extracted daily data on reported COVID-19
272 273	For every state and county in the United States, we extracted daily data on reported COVID-19 cases and deaths from a repository compiled by the Johns Hopkins Center for Systems Science
272 273 274	For every state and county in the United States, we extracted daily data on reported COVID-19 cases and deaths from a repository compiled by the Johns Hopkins Center for Systems Science and Engineering (CSSE) ⁹ . We calculated the time series of new cases and deaths as the
272 273 274 275	For every state and county in the United States, we extracted daily data on reported COVID-19 cases and deaths from a repository compiled by the Johns Hopkins Center for Systems Science and Engineering (CSSE) ⁹ . We calculated the time series of new cases and deaths as the difference between cumulative counts reported on consecutive days. In instances in which the
272 273 274 275 276	For every state and county in the United States, we extracted daily data on reported COVID-19 cases and deaths from a repository compiled by the Johns Hopkins Center for Systems Science and Engineering (CSSE) ⁹ . We calculated the time series of new cases and deaths as the difference between cumulative counts reported on consecutive days. In instances in which the reported cumulative count decreased from one day to the next, we assumed that there were zero
272 273 274 275 276 277	For every state and county in the United States, we extracted daily data on reported COVID-19 cases and deaths from a repository compiled by the Johns Hopkins Center for Systems Science and Engineering (CSSE) ⁹ . We calculated the time series of new cases and deaths as the difference between cumulative counts reported on consecutive days. In instances in which the reported cumulative count decreased from one day to the next, we assumed that there were zero new cases or deaths on each day until the cumulative count exceeded the previous maximum. In

281 Mathematical model

282	We constructed a deterministic mathematical model relating reported cases and deaths to
283	unobserved COVID-19 natural history. A flexible function for R_t determines the number of
284	individuals infected on a given day, and the model then tracks the progression of the infected
285	cohort through health states of increasing disease severity, with modelled quantities— A_t
286	(Asymptomatic), S_t (Symptomatic), V_t (Severe), and D_t (Death)—reflecting the number of
287	individuals entering a given health state on day t. From each health state, an individual can either
288	recover or progress to the next health state, with this transition governed by a defined delay
289	distribution. Ultimately, the model estimates an expected number of reported cases and deaths on
290	each day, which are fit to observed data via negative binomial likelihood functions.

291 New infections

We modelled the daily number of newly-infected individuals (A_t) entering the *Asymptomatic* state. For each modelled location, we specified a random intercept (A_0) 28 days before the first reported COVID-19 case, and calculated changes in A_t as a function of the effective reproduction number (R_t) and the serial interval (z), measured in days.

$$A_{t+1} = A_t R_t^{\frac{1}{2}} \quad for \ t \ge 0$$
[1]

We modelled the time trend in R_t using a log-transformed cubic b-spline $(X_{R,t})$ with knots every 5 days, allowing flexibility in the evolution of the epidemic curve over time. Penalties on first and second differences of the spline parameters were used to dampen oscillations not supported by the data. We assumed that individuals can only be infected once and multiplied the spline by the fraction of the population (*N*) uninfected at each timepoint, penalizing R_t towards zero as the population ever-infected approaches 100%.

303
$$R_t = X_{R,t} \left(1 - \frac{\sum_{i=0}^t A_i}{N} \right)$$
[2]

304 Disease progression

We assumed that a fraction of individuals with asymptomatic disease (p_s) progress to the *Symptomatic* state. The delay from infection to symptoms was assumed to follow a Gamma distribution, with $\rho_{s,i}$ representing the fraction progressing between *i* and *i*+1 days after infection, among those progressing to the symptomatic state.

309
$$S_t = \sum_{i=0}^t A_{t-i} p_S \rho_{S,i}$$
[3]

Similarly, a fraction of individuals in the *Symptomatic* state (p_V) were assumed to progress to the *Severe* state, with Gamma-distributed delay distribution $\rho_{V,i}$. A fraction of individuals with severe disease $(p_{D,t})$ die, with Gamma-distributed delay distribution $\rho_{D,i}$.

313
$$V_t = \sum_{i=0}^t S_{t-i} \, p_V \rho_{V,i}$$
[4]

314
$$D_t = \sum_{i=0}^t V_{t-i} p_{D,t} \rho_{D,i}$$
 [5]

With the exception of $p_{D,t}$, disease progression parameters were not allowed to vary over time. For $p_{D,t}$ we assumed higher values applied in early 2020, reflecting higher case fatality among individuals with severe disease early in the epidemic due to later presentation and lower effectiveness of treatment at that time. We modeled the time trend in $p_{D,t}$ as a sigmoid curve (operationalized using the Normal cumulative distribution function Φ) with an inflection point on May 1 2020. The odds ratio OR_{p_D} describes the elevated case fatality early in the epidemic,

321 and p_{D0} defines the progression probability after early 2020. In Equation 6, μ is equal to the

number of days between the start of the model (*t*=0) and May 1st 2020, and σ is equal to 21 days.

323
$$\frac{p_{D,t}}{1-p_{D,t}} = \frac{p_{D,0}}{1-p_{D,0}} \left(1 + \Phi\left(\frac{\mu-t}{\sigma}\right) OR_{p_D} \right)$$
[6]

While vaccination would also affect disease progression probabilities, we assumed that
 vaccination coverage was insufficient to impact disease natural history during the study period.

326 Infection fatality ratio

327 We assumed that the infection fatality ratio (IFR) differs across states and counties, reflecting 328 differences in the age distribution of the epidemic and differences in the prevalence of medical 329 risk factors for severe COVID-19 disease. First, we calculated the age distribution of infections 330 for each state, based on the reported age distribution of COVID-19 deaths²⁵ and published agespecific IFRs.²⁶ Second, we used these age distributions to calculate an average IFR for each 331 332 state, weighting the age-specific IFRs by the fraction of the population in each age group. This 333 produced a national average IFR of 0.35, which we believe to be implausibly low; we rescaled state-level values to produce a national average IFR of 0.5%.²⁷ As the age-distribution of 334 335 COVID-19 deaths was not available at the county-level, we estimated county-level IFR values 336 by multiplying the state-average IFR by the prevalence of medical risk factors for severe COVID-19 disease in each county relative to the rest of the state.²⁸ To understand the 337 338 implications uncertainty in the IFR for modelled estimates of the infected population, we plotted 339 the relationship between these two quantities in the fitted model outcomes.

340 Diagnosis

We assumed that infected individuals could be diagnosed from the Asymptomatic, Symptomatic, 341 342 or Severe states, and that diagnosis would not affect disease progression. We assumed that 343 diagnosis in the Asymptomatic state only occurs among individuals who will not progress to the Symptomatic state. The daily number of these diagnoses is denoted \hat{A}_t (with the ^ used to 344 indicate quantities related to diagnosis). The fraction of these individuals diagnosed $(q_{A,t})$ was 345 346 assumed to vary over time, to allow for changes in case ascertainment over the course of the epidemic. The delay to diagnosis was defined by $\hat{\rho}_{A,i}$, which is described by a Gamma 347 348 distribution.

349
$$\hat{A}_t = \sum_{i=0}^t A_{t-i} q_{A,t-i} \hat{\rho}_{A,i} (1-p_S)$$
[7]

350 To estimate the number diagnosed from the *Symptomatic* state (\hat{S}_t) we assumed a time-varying 351 probability of diagnosis $q_{s,t}$ and delay to diagnosis $\hat{\rho}_{s,i}$.

352
$$\hat{S}_{t} = \sum_{i=0}^{t} S_{t-i} q_{S,t-i} \hat{\rho}_{S,i}$$
[8]

353 The number diagnosed from the *Severe* state (\hat{V}_t), was calculated based on a time-invariant 354 probability of diagnosis (q_V) and delay to diagnosis $\hat{\rho}_{V,i}$. These were applied after subtracting 355 individuals developing severe disease who had been previously diagnosed at *Symptomatic* (\bar{V}_t).

356
$$\bar{V}_t = \sum_{i=0}^t S_{t-i} q_{S,t-i} p_V \rho_{V,i}$$
[9]

357
$$\hat{V}_t = \sum_{i=0}^t (V_{t-i} - \bar{V}_{t-i}) q_V \hat{\rho}_{V,i}$$
[10]

358 Time-varying diagnosis probabilities $(q_{A,t}, q_{S,t})$ were calculated as a function of q_V :

359
$$q_{S,t} = q_V X_{q_S,t}$$
 [11]

$$360 q_{A,t} = q_V X_{q_S,t} R R_{q_A} [12]$$

In equations 11 and 12, $X_{q_S,t}$ is a logit-transformed cubic b-spline with knots spaced 21 days apart, with penalties on first and second differences of the spline parameters. RR_{q_A} is constrained to fall in the unit interval, so that that $q_{A,t} \le q_{S,t} \le q_V$ for all *t*.

364 *Reporting*

We assumed that all diagnosed COVID-19 cases were reported. The number of diagnoses reported on a given day (\dot{C}_t , with the '·' used to indicate quantities related to reporting) was calculated as the sum of diagnoses from *Asymptomatic*, *Symptomatic* and *Severe* states, with reporting delay $\dot{\rho}_{c,i}$.

369
$$\dot{C}_t = \sum_{i=0}^t \left(\hat{A}_{t-i} + \hat{S}_{t-i} + \hat{V}_{t-i} \right) \dot{\rho}_{C,i}$$
[13]

The reported number of COVID-19 deaths (\dot{D}_t) were calculated from the number of diagnosed individuals who subsequently died (\hat{D}_t) . \hat{D}_t was calculated as the sum of deaths among individuals diagnosed from the *Symptomatic* and *Severe* states, represented by the first and second terms in equation 14, respectively. We assumed that all deaths among diagnosed COVID-19 cases were reported, with reporting delay $\dot{\rho}_{D,i}$.

375
$$\widehat{D}_{t} = \left(\sum_{i=0}^{t} \overline{V}_{t-i} \, p_{D,t} \rho_{D,i}\right) + \left(\sum_{i=0}^{t} (V_{t-i} - \overline{V}_{t-i}) \, q_{V} p_{D,t} \rho_{D,i}\right)$$
[14]

376
$$\dot{D}_t = \sum_{i=0}^t \widehat{D}_{t-i} \dot{\rho}_{D,i}$$
 [15]

Data likelihood

378 We specified negative binomial likelihood functions to fit the model to observed cases $(Y_{C,t})$ and 379 death data $(Y_{D,t})$.

$$Y_{C,t} \sim NegBin(\dot{C}_t, \phi_C)$$

 $Y_{D,t} \sim NegBin(\dot{D}_t, \phi_D)$

380	To account for variation in daily reported cases and deaths, we implemented the likelihood using
381	a seven-day moving average of input data and modeled values. The negative binomial dispersion
382	parameters (ϕ_c , ϕ_D) were estimated simultaneously, allowing for additional variance in the
383	observed time series.

384 Model parameters

385 Model parameters are shown in Table 1.

Table 1: Model parameters

Model Parameter	Mean, std. Deviation	Distribution	Туре	Source
Log Of New Infections At T=0 (A_0)	0,10	Normal(0,10)	prior	Assumed
$X_{R,t}$ Spline Parameters	0,3	Normal(0,3)	prior	Assumed
First Derivative of $X_{R,t}$ Spline Parameters	0,0.5	Normal(0,0.5)	prior	Assumed
Second Derivative of $X_{R,t}$ Spline Parameters	0,0.1	Normal(0,0.1)	prior	Assumed
Serial Interval	5.8, 0.5	Gamma(129.1, 22.25)	prior	29
Probability of Developing Symptoms If Infected	0.59, 0.16	Beta(5.14, 3.53)	prior	30-33
Probability of Becoming Severely Ill If Symptomatic	0.09, 0.06	Beta(1.89, 20.00)	prior	35
Probability of Death for All Infections (national average)	0.005, 0.001	Beta(15.9, 3167)	prior	26,27
Probability of Death for Severe Infections	0.15, 0.03	Beta(28.2, 162.3)	prior	35

Rate Ratio, Diagnosis at Asymptomatic Vs. Symptomatic	0.1, 0.07	Beta(2,18)	prior	Assumed
Rate Ratio, Diagnosis at Symptomatic Vs. Severe	0.5, 0.22	Beta(2,2)	prior	Assumed
Probability of Diagnosis at Severe	0.72, 0.16	Beta(20,5)	prior	Assumed
Case Dispersion Parameter $(1/\sigma)^2 *$	0.8, 0.6	Half-Normal(0,1)	prior	36
Death Dispersion Parameter $(1/\sigma)^2 *$	0.8, 0.6	Half-Normal(0,1)	prior	36
Time from Infected to Symptomatic (Days)	5.6, 3.1	Gamma(3.41, 0.61)	fixed	37
Time from Symptomatic to Severe (Days)	7.5, 5.8	Gamma(1.72, 0.22)	fixed	38
Time from Severe to Death (Days)	9.1, 6.3	Gamma(2.10, 0.23)	fixed	39
Scaling Factor: Time to Diagnosis Relative to Time in Symptomatic State	0.5, 0.22	Beta(2,2)	prior	Assumed
Scaling Factor: Time to Diagnosis Relative to Time in Severe State	0.5, 0.22	Beta(2,2)	prior	Assumed
Case Reporting Delay	2.2, 1.5	Gamma(2.2, 1)	prior	Assumed
Death Reporting Delay	2.2, 1.5	Gamma(2.2, 1)	prior	Assumed

387

388 Model implementation

The model was implemented in R using the rstan package.⁴⁰ The model initializes 28 days before 389 390 the first reported case or death. Given the delay from infection to death, we chose 28 days to 391 allow the model to generate the necessary number of new infections to plausibly result in a death 392 early in the observed time series. The model is fit to data from each county or state separately. For state-level results we estimated outcomes using a Hamiltonian Monte Carlo algorithm.⁴¹ The 393 394 model ran for 3000 iterations (2000 burn-in) on 5 chains, and 4000 samples (across 4 chains) 395 from the posterior were included in these results. Counties were fit using an optimization routine 396 that reports the maximum a posteriori estimate, which represents an estimate of the mode of the 397 posterior distribution of the model parameters.

398 *covidestim* Package

The *covidestim* package is a package for the R programming language, suitable for public as well as research use. It can accommodate a number of data inputs. Users may enter a vector of daily case counts and/or daily death counts. These data sources can be used in combination, so long as they are the same length and cover the same time period; days with no observed events may be represented with zeroes.

The package contains default model priors for progression probabilities and delays, detection probabilities and delays, and reporting delays associated with each data type. Users have the ability to override these defaults, though we recommend that they only specify priors for reporting delays; we do not recommend that users change default priors on parameters related to the natural history of COVID-19.

409 **Covidestim.org and code repositories**

410 We produce daily estimates of COVID-19 infections and the effective reproduction number of 411 SARS-CoV-2 at the state- and county-levels at https://covidestim.org. To allow for daily 412 production of model estimates for all U.S. counties and states, we developed several tools. The 413 covidestim Docker image is a container which allows for model execution in any HPC or cloud 414 environment, and is the easiest way to begin using the *covidestim* R package. The *covidestim*-415 sources repository enables automated, version-controlled, reproducible data cleaning of four 416 different case/death data sources by leveraging Git's submodules feature. Finally, the *dailyFlow* repository uses the Nextflow workflow engine⁴² to clean the data, orchestrate 3200+ model runs 417 418 within three supported execution environments (local, HPC, cloud), and export the results for 419 research use and for web consumption. These repositories can be found at 420 https://github.com/covidestim, and contain extensive documentation.

Acknowledgments: We thank Jeffrey Eaton for his thoughts on statistical analysis.

References

424	1.	Coronavirus in the U.S.: Latest Map and Case Count. Retrieved from
425		https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html
426	2.	Coronavirus. Retrieved from
427		https://www.washingtonpost.com/graphics/2020/national/coronavirus-us-cases-
428		deaths/?itid=hp_pandemic%20test
429	3.	Oran DP and Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative
430		review. Annals of internal medicine. 2020; 173(5): 362-367.
431	4.	Hitchings MDT, Dean NE, Garcia-Carreras B, Hladish TJ, Huang AT, Yang B, Cummings
432		DAT. The Usefulness Of SARS-CoV-2 Test-Positive Proportion As A Surveillance Tool.
433		American Journal of Epidemiology. 2021; 190(7):1396–1405.
434		https://doi.org/10.1093/aje/kwab023
435	5.	Pitzer VE, Chitwood MH, Havumaki J, Menzies NA, Perniciaro S, Warren JL, et al. The
436		impact of changes in diagnostic testing practices on estimates of COVID-19 transmission in
437		the United States. American Journal of Epidemiology. 2021;
438		https://doi.org/10.1093/aje/kwab089
439	6.	Weinberger D, Cohen T, Crawford F, Mostashari F, Olson D, Pitzer VE, et al., Estimating
440		the early death toll of COVID-19 in the United States. [Preprint]. 2020 [Cited 2020 July 13]
441		Available from: <u>https://doi.org/10.1101/2020.04.15.20066431</u> .
442	7.	Gostic KM, McGough L, Baskerville E, Abbott S, Joshi K, Tedijanto C, et al. Practical
443		considerations for measuring the effective reproductive number, Rt. PLoS Comput. Biol.
444		2021; 16(12): e1008409. https://doi.org/10.1371/journal.pcbi.1008409
445	8.	Unwin HJT, Mishra S, Bradley VC, Gandy A, Mellan TA, Coupland H, et al. State-level
446		tracking of COVID-19 in the United States. Nat. Commun. 2020; 11, 6189
447		https://doi.org/10.1038/s41467-020-19652-6
448	9.	COVID-19 Portal, Center for the Ecology of Infection Diseases, University of Georgia [Cited
449		2021 July 10]. Available at: https://www.covid19.uga.edu/nowcast.html
450	10	. Considerations for implementing and adjusting public health and social measures in the
451		context of COVID-19. Geneva: World Health Organization;
452		https://apps.who.int/iris/bitstream/handle/10665/336374/WHO-2019-nCoV-
453		Adjusting_PH_measures-2020.2-eng.pdf?sequence=1&isAllowed=y
454	11	. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliot J, Hofmann C, Hausner MA, et al. Rapid
455		Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med.
456		2020; 383:1085-1087. DOI: 10.1056/NEJMc2025179
457	12	. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA. Longitudinal observation
458		and decline of neutralizing antibody responses in the three months following SARS-CoV-2
459		infection in humans. Nat Microbiol. 2020; 5:1598–1607 https://doi.org/10.1038/s41564-020-
460		<u>00813-8</u>
461	13	. Bajema KL, Wiegan RE, Cuffe K, Patel SV, Iachan R, Lim T. Estimated SARS-CoV-2
462		Seroprevalence in the US as of September 2020. JAMA Intern Med. November 24, 2020;
463		doi:10.1001/jamainternmed.2020.7976
464	14	. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
465		time. Lancet Inf. Dis. May 1, 2020; 20(5):533-534. DOI: <u>https://doi.org/10.1016/S1473-</u>
466		<u>3099(20)30120-1</u>

- 467 15. Nationwide Commercial Laboratory Seroprevalence Survey. [Cited 23 March, 2020] 468 Available at: https://data.cdc.gov/Laboratory-Surveillance/Nationwide-Commercial-469 Laboratory-Seroprevalence-Su/d2tw-32xv
- 470 16. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020; 370(6521):1227-471 472 1230. doi: 10.1126/science.abd7728.
- 473 17. Qureshi AI, Baskett WI, Huang W, Lobanova I, Naqvi SH, Shyu C. Reinfection with Severe 474 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial 475 Laboratory Testing. Clinical Infectious Diseases. 2021; https://doi.org/10.1093/cid/ciab345
- 476 18. Li T, White LF. Bayesian back-calculation and nowcasting for line list data during the COVID-19 pandemic. PLOS Computational Biology. 2021; 17(7): e1009210. 477 478 https://doi.org/10.1371/journal.pcbi.1009210
- 479 19. Flaxman S, Mishra S, Gandy A, Unwin JT, Mellan TA, Coupland H, et al. Estimating the 480 effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020; 584: 481 257-261 https://doi.org/10.1038/s41586-020-2405-7
- 482 20. Leung K, Wu JT & Leung GM. Real-time tracking and prediction of COVID-19 infection 483 using digital proxies of population mobility and mixing. Nat Commun. 2021; 12: 1501 484 https://doi.org/10.1038/s41467-021-21776-2
- 21. Kishore N, Taylor AR, Jacob PE, Vembar N, Cohen T, Buckee CO, et al. The relationship between human mobility measures and SAR-CoV-2 transmission varies by epidemic phase 486 and urbanicity: results from the United States. [Preprint] 2021. [Cited 15 July 2021]. 488 Available from: https://www.medrxiv.org/content/10.1101/2021.04.15.21255562v1
 - 22. Nouvellet P, Bhatia S, Cori A, Ainslie KEC, Baguelin M, Bhatt S, et al. Reduction in mobility and COVID-19 transmission. Nat Commun. 2021; 12: 1090 https://doi.org/10.1038/s41467-021-21358-2
 - 23. COVID Data Tracker. "Variant Proportions" [Cited 8 June 2021] Available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions
 - 24. The COVID Tracking Project. [Cited 15 January 2021] Available at: https://covidtracking.com/

485

487

489

490

491

492

493

494

- 496 25. National Center for Health Statistics. "Provisional COVID-19 Death Counts by Sex, Age, 497 and State" [Cited 15 January 2021] Available at: https://data.cdc.gov/NCHS/Provisional-498 COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku
- 499 26. O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. 500 Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021; 590; 140–145 501 https://doi.org/10.1038/s41586-020-2918-0
- 27. Levin AT, Hanage WP, Owusu-Boaitev N, Cochran KB, Walsh SP, Meyerowitz-Katz G. 502 Assessing the age specificity of infection fatality rates for COVID-19: systematic review, 503 504 meta-analysis, and public policy implications. Eur J Epidemiol. 2020; 35: 1123–1138. 505 https://doi.org/10.1007/s10654-020-00698-1
- 506 28. Razzaghi H. Wang Y. Lu H. et al. Estimated County-Level Prevalence of Selected 507 Underlying Medical Conditions Associated with Increased Risk for Severe COVID-19 508 Illness — United States, 2018. MMWR Morb Mortal Wkly Rep 2020;69:945–950. DOI: 509 http://dx.doi.org/10.15585/mmwr.mm6929a1
- 510 29. X He, EH Lau, P Wu, Marshall KE, Dowling NF, Paz-Bailey G, et al. Temporal dynamics in 511 viral shedding and transmissibility of COVID-19. Nature medicine. 2020; 26(5): pp.672-675.

- 512 30. Poletti, P., Tirani, M., Cereda, D., Trentini, F., Guzzetta, G., Sabatino, G., Marziano, V., 513 Castrofino, A., Grosso, F., Del Castillo, G. and Piccarreta, R., 2020. Probability of symptoms 514 and critical disease after SARS-CoV-2 infection. arXiv preprint arXiv:2006.08471.
- 515 31. Oran, D.P. and Topol, E.J., 2020. Prevalence of asymptomatic SARS-CoV-2 infection: a 516 narrative review. Annals of internal medicine, 173(5), pp.362-367.
- 517 32. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. 518 Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 519 infections: A living systematic review and meta-analysis. PLOS Medicine. 2020; 17(9): e1003346. https://doi.org/10.1371/journal.pmed.1003346 520
- 521 33. O Byambasuren, M Cardona, K Bell, J Clark, M McLaws, P Glasziou (2020). "Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: 522 523 systematic review and meta-analysis." JAMMI. 5(4): 223-234. 524 https://doi.org/10.3138/jammi-2020-0030
- 525 34. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the 526 severity of coronavirus disease 2019: a model-based analysis. The Lancet Infectious 527 Diseases. 2020; 20(6): 669 - 677.
- 35. CDC COVID-19 Response Team. "Severe Outcomes Among Patients with Coronavirus 528 529 Disease 2019 (COVID-19) — United States, February 12-March 16, 2020." MMWR. 530 Morbidity and Mortality Weekly Report (2020) 69(12), 343--346. ISSN 0149-2195, 1545-861X, doi: 10.15585/mmwr.mm6912e2
 - 36. Gelman, A. Prior Choice Recommendations. Github. 2020 April 17 [Cited 2021 July 10]. Available from: https://github.com/stan-dev/stan/wiki/Prior-Choice-Recommendations
 - 37. SA Lauer, KH Grantz, O Bi, et al. "The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application." Annals of Internal Medicine (2020). 172(9), 577--582. ISSN 0003-4819, 1539-3704, doi: 10.7326/M20-0504
 - 38. F Zhou, T Yu, R Du, et al. "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study." The Lancet. (2020). 395(10229), 1054--1062. ISSN 01406736, doi: 10.1016/S0140-6736(20)30566-3
- 39. NM Linton, T Kobayashi, Y Yang, K Hayashi, AR Akhmetzhanov, S Jung, B Yuan, R 542 Kinoshita, H Nishiura. "Incubation Period and Other Epidemiological Characteristics of 2019 543 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly 544 Available Case Data." Journal of Clinical Medicine. (2020). 9(2), 538. ISSN 2077-0383, doi: 545 10.3390/jcm9020538
 - 40. Stan Development Team. RStan: the R interface to Stan. 2018 R package version 2.17.3. http://mc-stan.org
- 548 41. Hoffman MD and Gelman A. The No-U-Turn sampler: adaptively setting path lengths in 549 Hamiltonian Monte Carlo. J Mach Learn Res. 2012; 15(1): 1593-1623.
 - 42. Di Tommaso P, Chatzou M, Floden E, Barja PP, Palumbo E, Noterdame C. Nextflow enables reproducible computational workflows. Nat Biotechnol. 2017: 35, 316–319. https://doi.org/10.1038/nbt.3820

554 **Funding:**

531

532 533

534 535

536

537

538

539 540

541

546

547

550

551

552


- 555 KG reports grant from National Institutes of Health T32 GM007205 and Fogarty International
- 556 Center D43 TW010540
- VEP reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093 557

- 558 DMW reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093
- 559 JLW reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093
- 560 TC reports grants from National Institute of Allergy and Infectious Diseases R01 AI112438
- 561 NAM reports grants from National Institute of Allergy and Infectious Diseases R01 AI146555-562 01A1
- 563 JAS reports funding from the Centers for Disease Control and Prevention though the Council of
- 564 State and Territorial Epidemiologists (NU38OT000297-02) and the National Institute on Drug 565 Abuse (3R37DA01561217S1).
- 566 The funders had no role in study design, data collection and analysis, decision to publish, or 567 preparation of the manuscript.


569 **Author contributions:**

568


- 570 NAM and TC conceived and supervised the project. NAM and JS acquired funding. MR, KG,
- and JH curated data. MHC, MR, FK, VEP, JS, JW, DW, TC, and NAM contributed to the
- 572 development of the methodology. MHC, MR, FK, and NAM wrote the software. MHC, MR, and
- 573 NAM conducted the formal analysis. MHC, MR, and NS visualized results. Validation was
 574 performed by NAM and NS. MHC and NAM drafted the original manuscript. All authors
 575 contributed to the review and editing of the original manuscript.
- 577 **Competing interests:** DMW has received consulting fees from Pfizer, Merck, GSK, and 578 Affinivax for topics unrelated to this manuscript and is Principal Investigator on a research grant 579 from Pfizer on an unrelated topic. VEP has received reimbursement from Merck and Pfizer for 580 travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All 581 other authors have declared that no competing interest exist.
- 582 Data and materials availability: All data used in the main analysis are available for use at
 583 <u>https://github.com/covidestim/covidestim-sources</u>. The *covidestim* package is available for
 584 download at <u>https://github.com/covidestim/covidestim</u>.




1 Apr. 2020




1 Jul. 2020



1 Oct. 2020




1 Jan. 2021




Infections / 100k / day 0 100 200 300 400


1 May 2020




1 Aug. 2020




1 Nov. 2020






1 Jun. 2020



1 Sept. 2020



1 Dec. 2020

